R 1518

Drug Profile

R 1518

Alternative Names: R-1518

Latest Information Update: 19 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche; Valeant Pharmaceuticals International
  • Class Antivirals; Monosaccharides; Nucleosides; Triazoles
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 14 Nov 2003 ICN Pharmaceuticals is now called Valeant Pharmaceuticals International
  • 16 Jun 2003 Phase-I clinical trials in Hepatitis C treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top